ASRT NASDAQ
Assertio Holdings, Inc.
1W: +0.3%
1M: +0.8%
3M: +99.7%
YTD: +157.1%
1Y: +3709.4%
3Y: +290.4%
5Y: +1163.4%
$23.50
Last traded 2026-06-15 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
12 relationships11
As Filer
counterparties named
1
As Counterparty
mentioned by others
5
Rel. Types
2021-07-15
Earliest Filing
2025-10-10
Latest Filing
target: 3
partner: 3
supplier: 2
acquirer: 2
customer: 1
Counterparties (Filed by ASRT)
11 relationshipsCompanies named in ASRT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Spectrum Pharmaceuticals, Inc. | SPPI | customer | Wholly owned subsidiary of Assertio Holdings, Inc. that entered into an amended supply agreement for ROLVEDON drug subst | 2025-10-10 | View |
| Hanmi Pharmaceutical Co. Ltd. | — | supplier | Supplier of ROLVEDON drug substance that entered into an amended supply agreement with Spectrum Pharmaceuticals, Inc. | 2025-10-10 | View |
| Spectrum Pharmaceuticals, Inc. | — | target | Target of acquisition by Assertio Holdings, Inc. | 2023-10-10 | View |
| Spectrum Pharmaceuticals, Inc. | SPPI | target | Target company acquired by Assertio Holdings, Inc. via a merger agreement. | 2023-08-01 | View |
| Spade Merger Sub 1, Inc. | — | acquirer | Wholly owned subsidiary of Assertio Holdings, Inc. used as the merger vehicle to acquire Spectrum. | 2023-08-01 | View |
| Computershare Trust Company, N.A. | — | partner | Rights agent for the contingent value right (CVR) agreement entered into in connection with the merger. | 2023-08-01 | View |
| SLR Investment Corp. | SLRC | partner | Counterparty to the cancelled warrants held by Spectrum prior to the merger. | 2023-08-01 | View |
| Spectrum Pharmaceuticals, Inc. | — | target | Target company in the merger agreement with Assertio Holdings, Inc. | 2023-04-25 | View |
| Antares Pharma, Inc. | ATRS | acquirer | Assertio Holdings acquired Otrexup rights and assets from Antares Pharma in a $44 million transaction. | 2021-12-16 | View |
| Zyla Life Sciences | — | partner | Wholly owned subsidiary of Assertio Holdings, Inc. entering into an amended supply agreement. | 2021-07-15 | View |
| Cosette Pharmaceuticals, Inc. | — | supplier | Formerly G&W Laboratories, Inc., supplying INDOCIN Suppositories under an amended agreement. | 2021-07-15 | View |
Mentioned As Counterparty
1 mentionsOther companies that named ASRT in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-06-16 | Material Agreement; Acquisition/Disposition; Delisting Notice; Change in Control; Officer/Director C | Agreement Acquisition | View |
| 2026-05-18 | Other Events | View | |
| 2026-05-13 | Material Agreement; Termination of Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-05-08 | Regulation FD; Exhibits | View | |
| 2026-05-07 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-05 | Regulation FD; Exhibits | View | |
| 2026-05-04 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-04-29 | Regulation FD; Exhibits | View | |
| 2026-04-21 | Regulation FD; Exhibits | View | |
| 2026-04-14 | Acquisition/Disposition; Exhibits | Acquisition | View |
| 2026-04-09 | Material Agreement; Officer/Director Change; Regulation FD; Exhibits | Agreement | View |
| 2026-04-09 | Material Agreement; Officer/Director Change; Regulation FD; Exhibits | Agreement | View |
| 2026-03-16 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Other Events | View | |
| 2025-12-22 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2025-11-21 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-10-30 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-10-10 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR